Written by Renuka, Translated by Renuka, Medically Approved by Dr. Wichakorn, on 30 JUNE 2020

Trade Name: 
GENVOYA®

Generic Name: 
Elvitegravir 150 + Cobicistat 150+ Emtricitabine 200 mg + Tenofovir alafenamide10 mg

Mechanism of Action: 
Elvitegravir (Integrase Inhibitor), emtricitabine and tenofovir (NRTIs) directly suppress viral reproduction. Cobicistat (CYP3A Inhibitors) increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir.

Indication: 

• To treat HIV as a complete regimen for the treatment of HIV-1 infection in adults and children who are at least 12 years old and who weigh at least 55 pounds (25 kilograms) for who have not taken HIV medicines before, or to replace the current HIV treatment regimen of those who meet certain requirements, as determined by a health care provider.

• Genvoya is a complete HIV treatment regimen for the treatment of HIV infection and should not be used with other HIV medicines

Side effect:

• Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicine.

• New or worse kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys when starting and during treatment with GENVOYA. Your healthcare provider may tell you to stop taking GENVOYA if you develop new or worse kidney problems.

• Too much lactic acid in your blood (lactic acidosis). Too much lactic acid is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.

• Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

• The most common side effect of GENVOYA is nausea.

Drug Interaction:

• GENVOYA should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

• GENVOYA can alter the concentration of drugs metabolized by CYP3A or CYP2D6. Drugs that induce CYP3A can alter the concentrations of one or more components of GENVOYA. Consult the full prescribing information prior to and during treatment for potential drug-drug interactions.

Pregnancy:

• Not Recommended During Pregnancy

• Not recommended for use during pregnancy because of substantially lower exposures of cobicistat and elvitegravir during the second and third trimesters

• Should not be initiated in pregnant individuals. An alternative regimen is recommended for individuals who become pregnant during therapy with GENVOYA

Alcohol, Drug and Supplement:

The prescribing information of Genvoya does not mention the use of Genvoya with alcohol. Alcohol is not contraindicated with Genvoya, nor does it interact with Genvoya. However, alcohol damages the liver and is a strong risk factor for liver diseases. Genvoya is not recommended in patients with severe liver impairment

If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), like certain drugs that are used for high cholesterol, migraines, or mood problems. There are many drugs that must not be taken with Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide).

Availability:

Prescription only. Contact PULSE CLINIC.

References:

https://www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf

https://aidsinfo.nih.gov/drugs/553/genvoya/0/patient
https://www.drugs.com/genvoya.html